Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced four presentations of new preclinical data at the ...

Claruvis Pharmaceutical secured regulatory clearance for its genetically engineered neurotoxin marking a manufacturing ...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...

Genetic algorithms (GAs) mimic natural selection to solve complex optimization problems across engineering, AI, and science. By evolving a population of solutions through selection, crossover, and ...

Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene W ...

Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing machinery into the right cells efficiently, safely, and at the scale needed for ...

Hong Kong's digital hub and the Thai government innovation park signed agreements fostering bilateral technology development and regional collaboration.

Five Penn faculty members were elected to the American Academy of Arts and Sciences, an honorary society and independent ...

Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project ...

In vitro transcribed mRNA has lived up to its potential as a game-changing disruptive vaccine modality during the COVID-19 ...

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review ...

Cancer claims more than 10 million lives every year globally. Research shows that detecting cancer early can greatly improve ...